Comprehensive Stock Comparison
Compare Can-Fite BioPharma Ltd. (CANF) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AGIO | 48.0% revenue growth vs CANF's -9.3% |
| Quality / Margins | AGIO | -9.0% net margin vs CANF's -15.7% |
| Stability / Safety | CANF | Beta 0.36 vs AGIO's 0.91, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CANF | +169.9% vs AGIO's -14.9% |
| Efficiency (ROA) | AGIO | -29.0% ROA vs CANF's -114.0%, ROIC -26.6% vs -448.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Can-Fite BioPharma is a clinical-stage biopharmaceutical company developing small molecule drugs targeting inflammatory diseases and cancer. It generates revenue primarily through licensing agreements and milestone payments from partners — with no commercial products yet — as it advances its lead candidates through clinical trials. The company's competitive advantage lies in its proprietary A3 adenosine receptor platform, which targets a novel pathway for treating autoimmune and inflammatory conditions.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
AGIO leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). CANF leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Financial Metrics (TTM)
AGIO is the larger business by revenue, generating $45M annually — 80.0x CANF's $560,000. AGIO is the more profitable business, keeping -9.0% of every revenue dollar as net income compared to CANF's -15.7%. On growth, AGIO holds the edge at +43.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CANFCan-Fite BioPharm… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $560,000 | $45M |
| EBITDAEarnings before interest/tax | -$9M | -$470M |
| Net IncomeAfter-tax profit | -$9M | -$401M |
| Free Cash FlowCash after capex | -$8M | -$414M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +84.4% |
| Operating MarginEBIT ÷ Revenue | -16.0% | -10.6% |
| Net MarginNet income ÷ Revenue | -15.7% | -9.0% |
| FCF MarginFCF ÷ Revenue | -14.9% | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -36.1% | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +36.4% | -111.0% |
Valuation Metrics
| Metric | CANFCan-Fite BioPharm… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $14.2B | $2.25T |
| Enterprise ValueMkt cap + debt − cash | $14.2B | $2.25T |
| Trailing P/EPrice ÷ TTM EPS | -4.40x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 9999.00x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 6.34x | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
AGIO delivers a -31.2% return on equity — every $100 of shareholder capital generates $-31 in annual profit, vs $-2 for CANF. CANF carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to AGIO's 0.03x. On the Piotroski fundamental quality scale (0–9), AGIO scores 3/9 vs CANF's 1/9, reflecting mixed financial health.
| Metric | CANFCan-Fite BioPharm… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -2.1% | -31.2% |
| ROA (TTM)Return on assets | -114.0% | -29.0% |
| ROICReturn on invested capital | -4.5% | -26.6% |
| ROCEReturn on capital employed | -108.1% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 0.02x | 0.03x |
| Net DebtTotal debt minus cash | -$5M | -$49M |
| Cash & Equiv.Liquid assets | $5M | $89M |
| Total DebtShort + long-term debt | $104,000 | $40M |
| Interest CoverageEBIT ÷ Interest expense | -580.71x | — |
Total Returns (with DRIP)
A $10,000 investment in AGIO five years ago would be worth $6,363 today (with dividends reinvested), compared to $2,351 for CANF. Over the past 12 months, CANF leads with a +169.9% total return vs AGIO's -14.9%. The 3-year compound annual growth rate (CAGR) favors CANF at 20.6% vs AGIO's 6.1% — a key indicator of consistent wealth creation.
| Metric | CANFCan-Fite BioPharm… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | +2059.1% | +11.2% |
| 1-Year ReturnPast 12 months | +169.9% | -14.9% |
| 3-Year ReturnCumulative with dividends | +75.3% | +19.4% |
| 5-Year ReturnCumulative with dividends | -76.5% | -36.4% |
| 10-Year ReturnCumulative with dividends | -98.5% | -21.2% |
| CAGR (3Y)Annualised 3-year return | +20.6% | +6.1% |
Risk & Volatility
CANF is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than AGIO's 0.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CANF currently trades 96.3% from its 52-week high vs AGIO's 65.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CANFCan-Fite BioPharm… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.36x | 0.91x |
| 52-Week HighHighest price in past year | $4.93 | $46.00 |
| 52-Week LowLowest price in past year | $0.17 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +96.3% | +65.7% |
| RSI (14)Momentum oscillator 0–100 | 68.6 | 62.3 |
| Avg Volume (50D)Average daily shares traded | 4.3M | 948K |
Analyst Outlook
Wall Street rates CANF as "Buy" and AGIO as "Buy". Consensus price targets imply 52.6% upside for CANF (target: $7) vs 37.3% for AGIO (target: $42).
| Metric | CANFCan-Fite BioPharm… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $7.25 | $41.50 |
| # AnalystsCovering analysts | 4 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 20 | Feb 26 | Change |
|---|---|---|---|
| Can-Fite BioPharma … (CANF) | 100 | 33.04 | -67.0% |
| Agios Pharmaceutica… (AGIO) | 100 | 59.31 | -40.7% |
Agios Pharmaceutica… (AGIO) returned -36% over 5 years vs Can-Fite BioPharma … (CANF)'s -76%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Can-Fite BioPharma … (CANF) | $169500.00 | $674000.00 | +297.6% |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Can-Fite BioPharma … (CANF) | -40.7% | -11.7% | +71.3% |
| Agios Pharmaceutica… (AGIO) | -2.8% | -7.6% | -169.0% |
Agios Pharmaceuticals, Inc.'s net margin went from -3% (2016) to -8% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Can-Fite BioPharma … (CANF) | -90 | -1.08 | +98.8% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 5Free Cash Flow — 5 Years
Can-Fite BioPharma Ltd. generated $-8M FCF in 2024 (+23% vs 2021). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
CANF vs AGIO: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is CANF or AGIO a better buy right now?
Analysts rate Can-Fite BioPharma Ltd. (CANF) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CANF or AGIO?
Over the past 5 years, Agios Pharmaceuticals, Inc. (AGIO) delivered a total return of -36.4%, compared to -76.5% for Can-Fite BioPharma Ltd. (CANF). A $10,000 investment in AGIO five years ago would be worth approximately $6K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AGIO returned -21.2% versus CANF's -98.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CANF or AGIO?
By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd. (CANF) is the lower-risk stock at 0.36β versus Agios Pharmaceuticals, Inc.'s 0.91β — meaning AGIO is approximately 151% more volatile than CANF relative to the S&P 500. On balance sheet safety, Can-Fite BioPharma Ltd. (CANF) carries a lower debt/equity ratio of 2% versus 3% for Agios Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — CANF or AGIO?
Agios Pharmaceuticals, Inc. (AGIO) is the more profitable company, earning -764.0% net margin versus -1169.1% for Can-Fite BioPharma Ltd. — meaning it keeps -764.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AGIO leads at -873.9% versus -1206.2% for CANF. At the gross margin level — before operating expenses — CANF leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — CANF or AGIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is CANF or AGIO better for a retirement portfolio?
For long-horizon retirement investors, Can-Fite BioPharma Ltd. (CANF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.36)). Both have compounded well over 10 years (CANF: -98.5%, AGIO: -21.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between CANF and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.